• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

Emerg Infect Dis. Oseltamivir-Resistant Influenza Viruses A (H1N1), Norway, 2007?08

Giuseppe

Emeritus
Abstract. Oseltamivir-Resistant Influenza Viruses A (H1N1), Norway, 2007?08 (Emerg Infect Dis, edited)

DOI: 10.3201/eid1502.081031
Suggested citation for this article: Hauge SH, Dudman S, Borgen K, Lackenby A, Hungnes O. Oseltamivir-resistant influenza viruses A (H1N1), Norway, 2007?08. Emerg Infect Dis. 2009 Feb; [Epub ahead of print]
[Original Full Document: LINK. EDITED.]

Oseltamivir-Resistant Influenza Viruses A (H1N1), Norway, 2007?08

Siri H. Hauge, Susanne Dudman, Katrine Borgen, Angie Lackenby, and Olav Hungnes

Author affiliations: Norwegian Institute of Public Health, Oslo, Norway (S.H. Hauge, S. Dudman, K. Borgen, O. Hungnes); and Health Protection Agency, London, UK (A. Lackenby)


In Norway in January 2008, unprecedented levels of oseltamivir resistance were found in 12/16 influenza viruses A (H1N1) tested. To investigate the epidemiologic and clinical characteristics of these viruses, we used sequence analysis to test all available subtype H1N1 viruses from the 2007?08 season for resistance. Questionnaires from physicians provided information on predisposing diseases, oseltamivir use, symptoms, and complications. Clinical data were obtained for 265 patients. In total, 183 (67.3%) of 272 viruses were oseltamivir resistant. Resistance was not associated with prior use of antiviral drugs. Symptoms and hospitalization rates did not differ for patients infected with a resistant or a susceptible virus. Oseltamivir-resistant influenza viruses A (H1N1) did not show diminished capability to spread in the absence of selective pressure. The ability of these viruses to sustain their fitness and spread among persons should be considered when shaping future strategies for treating and preventing seasonal and pandemic influenza.

-
-----
 

Attachments

Re: Emerg Infect Dis. Oseltamivir-Resistant Influenza Viruses A (H1N1), Norway, 2007?08

Abstract. Oseltamivir-Resistant Influenza Viruses A (H1N1), Norway, 2007?08 (Emerg Infect Dis, edited)

DOI: 10.3201/eid1502.081031
Suggested citation for this article: Hauge SH, Dudman S, Borgen K, Lackenby A, Hungnes O. Oseltamivir-resistant influenza viruses A (H1N1), Norway, 2007?08. Emerg Infect Dis. 2009 Feb; [Epub ahead of print]
[Original Full Document: LINK. EDITED.]

Oseltamivir-Resistant Influenza Viruses A (H1N1), Norway, 2007?08

Siri H. Hauge, Susanne Dudman, Katrine Borgen, Angie Lackenby, and Olav Hungnes

Author affiliations: Norwegian Institute of Public Health, Oslo, Norway (S.H. Hauge, S. Dudman, K. Borgen, O. Hungnes); and Health Protection Agency, London, UK (A. Lackenby)


In Norway in January 2008, unprecedented levels of oseltamivir resistance were found in 12/16 influenza viruses A (H1N1) tested. To investigate the epidemiologic and clinical characteristics of these viruses, we used sequence analysis to test all available subtype H1N1 viruses from the 2007?08 season for resistance. Questionnaires from physicians provided information on predisposing diseases, oseltamivir use, symptoms, and complications. Clinical data were obtained for 265 patients. In total, 183 (67.3%) of 272 viruses were oseltamivir resistant. Resistance was not associated with prior use of antiviral drugs. Symptoms and hospitalization rates did not differ for patients infected with a resistant or a susceptible virus. Oseltamivir-resistant influenza viruses A (H1N1) did not show diminished capability to spread in the absence of selective pressure. The ability of these viruses to sustain their fitness and spread among persons should be considered when shaping future strategies for treating and preventing seasonal and pandemic influenza.

-
-----
A blueprint for pandemic swine H1N1.
 
Back
Top